Browsing Tag
Aflibercept
2 posts
Aflibercept 8 mg in diabetic macular edema first to achieve sustained vision gains with up to 83% of patients extended to 16-24 weeks at two years
Not intended for U.S. and UK Media Berlin, June 29, 2023 – Bayer today announced the two-year (96 weeks) topline results of the pivotal clinical trial PHOTON investigating its novel aflibercept 8 mg with extended dosing regimens of up to 24 weeks in diabetic macular edema (DME) compared to the current standard of care EyleaTM
Aflibercept 8 mg first to achieve extended injection intervals of 16 weeks in up to 89% of patients
////// Science for a better life